Unnamed: 0,title,date,stock,sentiment
114863.0,"UPDATE: AVEO Says Tivozanib Assigned PDUFA Target Action Date For Mar. 31, 2021",2020-06-01 13:20:00-04:00,AVEO,neutral
114864.0,Shares Of AVEO Spike Higher After Company Issues Press Release On FDA Acceptance On Drug Application,2020-06-01 13:16:00-04:00,AVEO,positive
114865.0,AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma,2020-06-01 13:15:00-04:00,AVEO,positive
114866.0,72 Biggest Movers From Friday,2020-06-01 04:53:00-04:00,AVEO,neutral
114867.0,50 Stocks Moving In Friday's Mid-Day Session,2020-05-29 12:15:00-04:00,AVEO,neutral
114868.0,AVEO Oncology Shares Tick Higher On Volume; Piper Sandler Raises Price Target From $18.50 To New Street-High Target At $26,2020-05-29 10:55:00-04:00,AVEO,positive
114869.0,"AVEO Oncology Shares Move To Session High On Volume, Now Over $8 Level, As Traders Circulate  Word Baird Raised Price Target On Stock From $15 To New Street High Of $24, Firm Says To Buy On Weakness",2020-05-29 10:02:00-04:00,AVEO,negative
114870.0,"Benzinga Pro's Top 5 Stocks To Watch For Fri., May 29, 2020: ZM, TSN, SGMS, CREX, AVEO",2020-05-29 08:04:00-04:00,AVEO,positive
114871.0,20 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-29 07:39:00-04:00,AVEO,neutral
114872.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,AVEO,positive
114873.0,AVEO Oncology Reports Phase 1b/2 DEDUCTIVE Study Of FOTIVDA In Combo With IMFINZI in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2,2020-05-29 07:11:00-04:00,AVEO,neutral
114874.0,AVEO Oncology Highlights TIVO-3 Final Overall Survival Results To Be Featured At ASCO,2020-05-29 07:01:00-04:00,AVEO,neutral
114875.0,70 Biggest Movers From Yesterday,2020-05-28 06:09:00-04:00,AVEO,neutral
114876.0,58 Stocks Moving In Wednesday's Mid-Day Session,2020-05-27 12:19:00-04:00,AVEO,neutral
114877.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-26 10:32:00-04:00,AVEO,neutral
114878.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-20 10:38:00-04:00,AVEO,neutral
114879.0,Stocks That Hit 52-Week Highs On Monday,2020-05-18 10:44:00-04:00,AVEO,neutral
114880.0,72 Biggest Movers From Yesterday,2020-05-05 04:29:00-04:00,AVEO,neutral
114881.0,55 Stocks Moving In Monday's Mid-Day Session,2020-05-04 12:39:00-04:00,AVEO,neutral
114882.0,Stocks That Hit 52-Week Highs On Monday,2020-05-04 10:35:00-04:00,AVEO,neutral
114883.0,"HC Wainwright & Co. Reiterates Buy on AVEO Pharmaceuticals, Raises Price Target to $10",2020-05-01 07:12:00-04:00,AVEO,neutral
114884.0,72 Biggest Movers From Yesterday,2020-05-01 05:29:00-04:00,AVEO,neutral
114885.0,61 Stocks Moving In Thursday's Mid-Day Session,2020-04-30 12:43:00-04:00,AVEO,neutral
114886.0,Mid-Day Market Update: Crude Oil Surges 20%; Chesapeake Energy Shares Plunge,2020-04-30 12:28:00-04:00,AVEO,negative
114887.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-30 10:31:00-04:00,AVEO,neutral
114888.0,"AVEO Pharma Shares At Session High, Up 13%; Hearing Baird Added Stock As 'Fresh Pick,' Reiterated Outperform Rating, $15 Price Target; Shares Last Traded Under $6",2020-04-30 10:19:00-04:00,AVEO,positive
114889.0,AVEO Pharmaceuticals Q1 EPS $(0.520) Down From $(0.060) YoY,2020-04-30 07:09:00-04:00,AVEO,neutral
114890.0,108 Biggest Movers From Yesterday,2020-04-30 05:30:00-04:00,AVEO,neutral
114891.0,54 Stocks Moving In Wednesday's Mid-Day Session,2020-04-01 12:30:00-04:00,AVEO,neutral
114892.0,"Piper Sandler Reiterates Overweight on AVEO Pharmaceuticals, Lowers Price Target to $18.5",2020-04-01 12:00:00-04:00,AVEO,negative
114893.0,AVEO Pharmaceuticals shares are trading higher after the company announced the submission of a new drug application to the FDA for Tivozanib in patients with relapsed or refractory renal cell carcinoma.,2020-04-01 08:13:00-04:00,AVEO,positive
114894.0,"H.C. Wainwright Reiterates Buy on AVEO Pharmaceuticals, Raises Price Target to $6",2020-04-01 08:11:00-04:00,AVEO,neutral
114895.0,31 Stocks Moving in Wednesday's Pre-Market Session,2020-04-01 07:18:00-04:00,AVEO,neutral
114896.0,6 Stocks Moving In Tuesday's After-Hours Session,2020-03-31 16:39:00-04:00,AVEO,neutral
114897.0,AVEO Pharmaceuticals shares are trading higher after the company announced the submission of a new drug application to the FDA for Tivozanib in patients with relapsed or refractory renal cell carcinoma.,2020-03-31 16:09:00-04:00,AVEO,positive
114898.0,AVEO Oncology Announces Submission Of New Drug Application To U.S. FDA For Tivozanib In Patients With Relapsed Or Refractory Renal Cell Carcinoma,2020-03-31 16:07:00-04:00,AVEO,neutral
114899.0,AVEO Oncology And Biodesix to Discontinue CyFi-2 Study Of Ficlatuzumab In Relapsed And Refractory AML In Response To Public Health Crisis,2020-03-27 16:40:00-04:00,AVEO,positive
114900.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 09:22:00-04:00,AVEO,positive
114901.0,90 Biggest Movers From Yesterday,2020-03-27 04:01:00-04:00,AVEO,neutral
114902.0,60 Stocks Moving In Thursday's Mid-Day Session,2020-03-26 12:33:00-04:00,AVEO,neutral
114903.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,AVEO,negative
114904.0,"HC Wainwright & Co. Maintains Buy on AVEO Pharmaceuticals, Raises Price Target to $4",2020-03-18 07:15:00-04:00,AVEO,neutral
114905.0,"AVEO Pharmaceuticals Q4 EPS $(0.28) Up From $(0.35) YoY, Sales $764K Down From $1.483M YoY",2020-03-16 16:08:00-04:00,AVEO,neutral
114906.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,AVEO,negative
114907.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,AVEO,negative
114908.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,AVEO,negative
114909.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,AVEO,neutral
114910.0,22 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-02-20 07:56:00-05:00,AVEO,neutral
114911.0,50 Stocks Moving in Thursday's Pre-Market Session,2020-02-20 07:30:00-05:00,AVEO,neutral
114912.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,AVEO,negative
114913.0,"AVEO Oncology Highlights Publication Of Phase 1b/2 Study Of Tivozanib In Advanced, Inoperable Liver Cancer In The British Journal Of Cancer",2020-02-12 16:28:00-05:00,AVEO,negative
114914.0,43 Healthcare Stocks Moving In Tuesday's After-Market Session,2020-01-28 23:40:00-05:00,AVEO,neutral
114915.0,AVEO Oncology Gives an Update on its Phase 1b Study of Ficlatuzumab,2020-01-27 07:09:00-05:00,AVEO,neutral
114916.0,50 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-08 08:31:00-05:00,AVEO,neutral
114917.0,AVEO Oncology Announces Erick Lucera CFO,2020-01-06 07:11:00-05:00,AVEO,neutral
114918.0,AVEO Oncology Highlights Publication Of Previously-Reported Data From Phase 3 TIVO-3 Study In Lancet Oncology Journal,2019-12-04 07:07:00-05:00,AVEO,neutral
114919.0,8 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-11-27 07:30:00-05:00,AVEO,neutral
114920.0,AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma,2019-11-18 06:02:00-05:00,AVEO,neutral
114921.0,30 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-11-15 08:14:00-05:00,AVEO,neutral
114922.0,AVEO pharmaceuticals shares are trading lower as a potential sell-off after the stock increased roughly 40% since Tuesday.,2019-11-14 15:05:00-05:00,AVEO,positive
114923.0,AVEO Pharmaceuticals shares are trading higher on continued momentum after the company reported Q3 EPS and sales results up from last year.,2019-11-13 13:43:00-05:00,AVEO,positive
114924.0,74 Biggest Movers From Yesterday,2019-11-13 04:42:00-05:00,AVEO,neutral
114925.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-11-12 12:12:00-05:00,AVEO,neutral
114926.0,AVEO Pharmaceuticals shares are trading higher after the company reported Q3 EPS and sales results up from last year.,2019-11-12 09:11:00-05:00,AVEO,positive
114927.0,6 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-11-12 07:41:00-05:00,AVEO,neutral
114928.0,28 Stocks Moving in Tuesday's Pre-Market Session,2019-11-12 07:15:00-05:00,AVEO,neutral
114929.0,AVEO Says Believes Cash And Cash Equivalents Of ~$57.7M Will Allow Co. To Fund Planned Operations Into Q2 Od 2021,2019-11-12 07:03:00-05:00,AVEO,positive
114930.0,"AVEO Pharmaceuticals Q3 EPS $0.1 Up From $(0.18) YoY, Sales $25.7M Up From $2.467M YoY",2019-11-12 07:02:00-05:00,AVEO,neutral
114931.0,23 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-11-07 08:04:00-05:00,AVEO,neutral
114932.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,AVEO,negative
114933.0,AVEO Pharmaceuticals shares are trading lower depsite no company-specific news. The stock has dropped approximately 44% over the past 5 trading sessions.,2019-11-06 10:18:00-05:00,AVEO,negative
114934.0,AVEO Pharmaceuticals shares are trading lower after the company announced a regulatory updated for Tivozanib in renal cell carcinoma.,2019-11-04 09:15:00-05:00,AVEO,neutral
114935.0,24 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-04 08:13:00-05:00,AVEO,neutral
114936.0,AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma,2019-11-04 07:13:00-05:00,AVEO,neutral
114937.0,AVEO Pharma shares are trading higher. Not seeing any news to justify the price action.,2019-10-16 11:32:00-04:00,AVEO,positive
114938.0,28 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-10-11 08:42:00-04:00,AVEO,neutral
114939.0,AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA,2019-09-30 07:01:00-04:00,AVEO,neutral
114940.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,AVEO,positive
114941.0,AVEO Oncology Announces Results from its Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma,2019-09-23 07:14:00-04:00,AVEO,neutral
114942.0,24 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-13 08:44:00-04:00,AVEO,neutral
114943.0,28 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-09-12 08:36:00-04:00,AVEO,neutral
114944.0,"A Look At Benzinga Pro's Most-Searched Tickers For September 11, 2019",2019-09-11 13:16:00-04:00,AVEO,neutral
114945.0,"Benzinga's Top Upgrades, Downgrades For September 11, 2019",2019-09-11 10:31:00-04:00,AVEO,positive
114946.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday., September 11, 2019",2019-09-11 09:24:00-04:00,AVEO,positive
114947.0,"H.C. Wainwright Upgrades AVEO Pharmaceuticals to Buy, Raises Price Target to $1.75",2019-09-11 07:18:00-04:00,AVEO,neutral
114948.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, September 10, 2019",2019-09-10 11:48:00-04:00,AVEO,positive
114949.0,22 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-10 09:02:00-04:00,AVEO,neutral
114950.0,AVEO Pharmaceuticals shares are trading higher after the company announced an update to the overall survival hazard ratio of 0.99 in Phase 3 trial of its TIVO-3.,2019-09-10 08:35:00-04:00,AVEO,positive
114951.0,AVEO Oncology Announces Updated Overall Survival Hazard Ratio Of 0.99 In Phase 3 TIVO-3 Trial Of Tivozanib In Renal Cell Carcinoma,2019-09-10 06:31:00-04:00,AVEO,neutral
114952.0,"The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved",2019-08-28 07:31:00-04:00,AVEO,positive
114953.0,16 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-08-26 08:44:00-04:00,AVEO,neutral
114954.0,The Week Ahead In Biotech: A Quiet One Ahead Of Labor Day Weekend,2019-08-25 15:06:00-04:00,AVEO,neutral
114955.0,31 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-09 09:00:00-04:00,AVEO,neutral
114956.0,25 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-08 08:35:00-04:00,AVEO,neutral
114957.0,"AVEO Pharmaceuticals Q2 EPS $(0.02) Beats $(0.06) Estimate, Sales $700K Miss $2.71M Estimate",2019-08-08 07:14:00-04:00,AVEO,negative
114958.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-02 09:07:00-04:00,AVEO,neutral
114959.0,100 Biggest Movers From Yesterday,2019-08-02 05:53:00-04:00,AVEO,neutral
114960.0,72 Stocks Moving In Thursday's Mid-Day Session,2019-08-01 12:16:00-04:00,AVEO,neutral
114961.0,"AVEO Pharmaceuticals shares are trading higher after the company announced that it has amended the license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which includes the U.S. and EU.",2019-08-01 09:49:00-04:00,AVEO,positive
114962.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-01 09:38:00-04:00,AVEO,neutral
114963.0,Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO Oncology,2019-08-01 06:28:00-04:00,AVEO,neutral
114964.0,Traders Circulating Bullish Blog Post Entitled 'AVEO Pharmaceuticals: Going From A Short-Term Trade To Long-Term Investment',2019-07-22 10:49:00-04:00,AVEO,positive
114965.0,Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.,2019-05-31 10:25:00-04:00,AVEO,negative
114966.0,"AVEO Pharmaceuticals Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $1.61M Miss $2.16M Estimate",2019-05-09 09:51:00-04:00,AVEO,negative
114967.0,AVEO Oncology Reports $2M Milestone Payment From EUSA Pharma For Commercialization Of FOTIVDA In Spain,2019-04-23 16:12:00-04:00,AVEO,neutral
114968.0,"Aveo Pharmaceuticals 10%+ Owner New Enterprise Associates 15, L.P. Buys 8,695,654 @ Avg Price: $0.57",2019-04-08 17:41:00-04:00,AVEO,neutral
114969.0,52 Biggest Movers From Yesterday,2019-04-05 05:55:00-04:00,AVEO,neutral
114970.0,44 Stocks Moving In Thursday's Mid-Day Session,2019-04-04 12:39:00-04:00,AVEO,neutral
114971.0,AVEO Pharmaceuticals Option Alert: Apr 18 $0.5 Calls at the Ask: 2000 @ $0.49 vs 7211 OI; Earnings 5/7 Before Open [est] Ref=$0.95,2019-04-04 11:17:00-04:00,AVEO,positive
114972.0,Aveo Pharmaceuticals shares are trading lower after the company announced and priced a $25 million public offering of common stock and short term warrants at $1.15 per share.,2019-04-04 09:52:00-04:00,AVEO,positive
114973.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Thurs., Apr. 4, 2019",2019-04-04 09:45:00-04:00,AVEO,positive
114974.0,32 Stocks Moving In Thursday's Pre-Market Session,2019-04-04 08:18:00-04:00,AVEO,neutral
114975.0,"The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut",2019-04-04 07:58:00-04:00,AVEO,neutral
114976.0,A Peek Into The Markets: US Stock Futures Flat Ahead Of Jobless Claims Data,2019-04-04 07:08:00-04:00,AVEO,neutral
114977.0,"8 Stocks To Watch For April 4, 2019",2019-04-04 04:53:00-04:00,AVEO,neutral
114978.0,AVEO Pharmaceuticals Prices 21.74M Share Public Offering @$1.15/Share+Warrant,2019-04-04 03:58:00-04:00,AVEO,positive
114979.0,"STAT News' Adam Feuerstein Responds To Twitter User Reference To 'AVEO Pump and Dump,' Tweets 'This is not hyperbole. I agree with him. SEC should halt trading in $AVEO. It's a...disgrace.'",2019-04-03 16:35:00-04:00,AVEO,negative
114980.0,AVEO Pharmaceuticals Reports Common Stock Offering; Size Not Disclosed,2019-04-03 16:04:00-04:00,AVEO,neutral
114981.0,"Benzinga Pro's Top 10 Most Searched Tickers For Morning Of Wed., Apr. 3, 2019",2019-04-03 09:58:00-04:00,AVEO,positive
114982.0,AVEO Pharmaceuticals shares are trading lower after the company reported that the CHMP has determined more mature OS data is need before drawing its conclusion for Tivo-3 trial.,2019-04-03 09:32:00-04:00,AVEO,positive
114983.0,Aveo Pharmaceuticals Says CHMP Has Determined More Mature OS Data Is Required Prior To Drawing Conclusion For Tivo-3 Trial,2019-04-03 06:21:00-04:00,AVEO,positive
114984.0,54 Biggest Movers From Yesterday,2019-04-03 05:42:00-04:00,AVEO,neutral
114985.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-04-02 12:27:00-04:00,AVEO,neutral
114986.0,AVEO Pharmaceuticals Option Alert: Jan 17 $1 Calls Sweep (2) near the Ask: 550 @ $0.7 vs 23435 OI; Earnings 5/7 Before Open [est] Ref=$1.49,2019-04-02 11:29:00-04:00,AVEO,positive
114987.0,AVEO Pharmaceuticals Option Alert: Apr 18 $2.5 Calls Sweep (123) near the Ask: 4977 @ $0.05 vs 24217 OI; Earnings 5/7 Before Open [est] Ref=$1.4648,2019-04-02 10:58:00-04:00,AVEO,positive
114988.0,32 Stocks Moving In Tuesday's Pre-Market Session,2019-04-02 08:20:00-04:00,AVEO,neutral
114989.0,"The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial",2019-04-02 07:30:00-04:00,AVEO,neutral
114990.0,AVEO Oncology To Present At The H.C. Wainwright Global Life Sciences Conference,2019-04-02 07:21:00-04:00,AVEO,neutral
114991.0,AVEO Pharmaceuticals shares are trading higher after the company presented Ficlatuzumab results at the American Association for Cancer Research 2019 Annual Meeting.,2019-04-02 06:41:00-04:00,AVEO,negative
114992.0,AVEO Pharmaceuticals shares are trading higher after the company presented Ficlatuzumab results at the American Association for Cancer Research 2019 Annual Meeting.,2019-04-01 17:10:00-04:00,AVEO,negative
114993.0,"AVEO, Biodesix Highlights Results From Phase Ib Expansion Cohort Trial Of Ficlatuzumab Presented At AACR Meeting",2019-04-01 16:06:00-04:00,AVEO,neutral
114994.0,58 Biggest Movers From Yesterday,2019-03-29 06:13:00-04:00,AVEO,neutral
114995.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-03-28 12:50:00-04:00,AVEO,neutral
114996.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Thurs., Mar. 28, 2019",2019-03-28 09:57:00-04:00,AVEO,positive
114997.0,AVEO Pharma shares are continuing lower after the stock climbed as much as 76% Wednesday before pulling back to end the day up 45%.,2019-03-28 09:20:00-04:00,AVEO,neutral
114998.0,71 Biggest Movers From Yesterday,2019-03-28 05:01:00-04:00,AVEO,neutral
114999.0,Mid-Afternoon Market Update: Shoe Carnival Surges On Upbeat Q4 Results; Inpixon Shares Plunge,2019-03-27 14:39:00-04:00,AVEO,positive
115000.0,60 Stocks Moving In Wednesday's Mid-Day Session,2019-03-27 13:08:00-04:00,AVEO,neutral
115001.0,Mid-Day Market Update: Crude Oil Down Over 1%; Syndax Pharmaceuticals Shares Spike Higher,2019-03-27 12:34:00-04:00,AVEO,negative
115002.0,Aveo Pharmaceuticals' shares are trading higher after a report the company could be acquired by Astrazeneca for about $800 million to $1.2 billion.,2019-03-27 11:34:00-04:00,AVEO,positive
115003.0,"UPDATE: Seeking Alpha Post On AstraZeneca For Aveo Shows Price In $800M-$1.2B Range; BZ NOTE: Author Of Post Has 5 Followers, Has Posted On SA Only 2 Times Previously, Disclosed Is Long Aveo",2019-03-27 09:05:00-04:00,AVEO,positive
115004.0,"'According to representatives from several large investment banks, it is their firm belief that Astrazeneca will acquire Aveo Oncology...' -Seeking Alpha Blog Post From TheBlueLion",2019-03-27 09:04:00-04:00,AVEO,neutral
115005.0,"AVEO Pharmaceuticals Q4 EPS $(0.03) Beats $(0.06) Estimate, Sales $1.48M Miss $2.4M Estimate",2019-03-14 17:13:00-04:00,AVEO,negative
115006.0,"The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis",2019-03-01 08:50:00-05:00,AVEO,neutral
115007.0,"AVEO Oncology Announces Oral Presentation of 'TIVO-3: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced RCC' at ASCO GU 2019",2019-02-17 08:36:00-05:00,AVEO,positive
115008.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-02-10 17:37:00-05:00,AVEO,neutral
115009.0,7 Biggest Price Target Changes For Monday,2019-02-04 09:52:00-05:00,AVEO,neutral
115010.0,"Benzinga's Top Upgrades, Downgrades For February 4, 2019",2019-02-04 09:09:00-05:00,AVEO,positive
115011.0,"B. Riley FBR Downgrades AVEO Pharmaceuticals to Neutral, Lowers Price Target to $1",2019-02-04 06:16:00-05:00,AVEO,negative
115012.0,10 Biggest Price Target Changes For Friday,2019-02-01 09:41:00-05:00,AVEO,neutral
115013.0,"Benzinga's Top Upgrades, Downgrades For February 1, 2019",2019-02-01 09:20:00-05:00,AVEO,positive
115014.0,"The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of  Titan's Opioid Disorder Treatment Implant",2019-02-01 09:10:00-05:00,AVEO,positive
115015.0,"H.C. Wainwright Downgrades AVEO Pharmaceuticals to Neutral, Lowers Price Target to $1",2019-02-01 07:04:00-05:00,AVEO,negative
115016.0,AVEO Pharmaceuticals shares are trading lower after the company announced they have accepted the FDA's recommendation to not submit a NDA for Tivozanib.,2019-01-31 10:02:00-05:00,AVEO,positive
115017.0,"UPDATE: AVEO Says Intends To Present Detailed Results Of TIVO-3 Study At ASCO GU Conference Feb. 14-16, 2019",2019-01-31 09:11:00-05:00,AVEO,neutral
115018.0,UPDATE: AVEO Says Co. Now Planning To Make New Drug Application Filing Decision Following Availability Of More Mature Overall Survival Results,2019-01-31 09:11:00-05:00,AVEO,positive
115019.0,"UPDATE: AVEO Says FDA Indicated 'preliminary OS results do not allay their concerns about the potential detriment in OS outlined in the complete response letter dated June 6, 2013'",2019-01-31 09:10:00-05:00,AVEO,neutral
115020.0,AVEO Oncology Reports Has Accepted Recommendation Of FDA Not To Submit New Drug Application For Tivozanib,2019-01-31 09:09:00-05:00,AVEO,positive
115021.0,AVEO Pharmaceuticals Option Alert: Jul 19 $2.5 Calls Sweep (3) near the Ask: 626 @ $0.35 vs 1152 OI; Earnings 3/12 Before Open [est] Ref=$1.86,2019-01-22 09:57:00-05:00,AVEO,positive
115022.0,UPDATE: Baird Believes 'AVEO's Fotivda has the potential to improve VEGF TKI therapy in renal cell cancer (RCC) both as monotherapy in later-line disease and as combination with PD-(L)1 inhibitors in earlier-line disease',2019-01-04 10:07:00-05:00,AVEO,negative
115023.0,"Benzinga's Top Upgrades, Downgrades For January 4, 2019",2019-01-04 09:14:00-05:00,AVEO,positive
115024.0,"Baird Initiates Coverage On AVEO Pharmaceuticals with Outperform Rating, Announces $3 Price Target",2019-01-04 08:00:00-05:00,AVEO,neutral
115025.0,"Baird Initiates AVEO Pharma With Outperform Rating, $3 Price Target",2019-01-03 16:18:00-05:00,AVEO,neutral
115026.0,"UPDATE: AVEO/Novartis Deal Provides Novartis Will Make 1-Time $2.3M Payment To AVEO On Or Before Jan. 2, 2019, Provide AV380 Drug Supply To Co. At No Charge",2018-12-19 06:14:00-05:00,AVEO,negative
115027.0,"UPDATE: AVEO AV380 Agreement With Novartis Provides For Continued Transfer To AVEO Of Preclinical, Technical, Manufacturing, Other Data, Materials Developed By Novartis For Program",2018-12-19 06:13:00-05:00,AVEO,positive
115028.0,AVEO Pharma 8-K Shows Deal With Novartis For AVEO's AV380 Program,2018-12-19 06:12:00-05:00,AVEO,neutral
115029.0,AVEO Oncology Announces Immuno-Oncology Clinical Collaboration With AstraZeneca,2018-12-12 07:08:00-05:00,AVEO,neutral
115030.0,Mid-Day Market Update: Crude Oil Down 5.5%; Bioblast Pharma Shares Spike Higher,2018-11-20 12:02:00-05:00,AVEO,negative
115031.0,AVEO Reports $2M Milestone Payment From EUSA Pharma Related To The German Commercialization Of FOTIVDA,2018-11-15 07:01:00-05:00,AVEO,neutral
115032.0,"AVEO Pharmaceuticals Q3 EPS $(0.18) Misses $(0.06) Estimate, Sales $2.467M Beat $680K Estimate",2018-11-09 07:04:00-05:00,AVEO,negative
115033.0,75 Biggest Movers From Yesterday,2018-11-07 04:00:00-05:00,AVEO,neutral
115034.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Nov. 6, 2018",2018-11-06 14:55:00-05:00,AVEO,positive
115035.0,60 Stocks Moving In Tuesday's Mid-Day Session,2018-11-06 12:36:00-05:00,AVEO,neutral
115036.0,"AVEO Pharma Shares Resume Trade, Up 2.2%",2018-11-05 16:50:00-05:00,AVEO,positive
115037.0,AVEO Pharma Shares To Resume Trade At 4:50 p.m. EST,2018-11-05 16:32:00-05:00,AVEO,positive
115038.0,"AVEO Pharmaceuticals Says Secondary Endpoint In Phase 3 TIVO-3 Trial Was Not Mature At The Time Of PFS Analysis; Says At Time Of Preliminary Analysis, There Was No Statistically Significant Difference In Overall Survival",2018-11-05 16:09:00-05:00,AVEO,negative
115039.0,AVEO Pharmaceuticals Reports Phase 3 TIVO-3 Trial Of Tivozanib In Renal Cell Carcinoma Met Primary Endpoint,2018-11-05 16:07:00-05:00,AVEO,neutral
115040.0,AVEO Pharma Shares Halted News Pending,2018-11-05 16:00:00-05:00,AVEO,positive
115041.0,AVEO Pharmaceuticals Option Alert: Nov 16 $4.5 Calls Sweep (29) near the Ask: 1235 @ $0.35 vs 1316 OI; Earnings 11/12 Before Open [est] Ref=$2.6199,2018-11-05 14:39:00-05:00,AVEO,positive
115042.0,20 Stocks Moving In Wednesday's Pre-Market Session,2018-10-24 08:03:00-04:00,AVEO,neutral
115043.0,58 Biggest Movers From Yesterday,2018-10-23 05:09:00-04:00,AVEO,neutral
115044.0,"Benzinga's Week Ahead: Can Tech Earnings Restore The Rally? Amazon, Google To Report",2018-10-22 12:49:00-04:00,AVEO,positive
115045.0,45 Stocks Moving In Monday's Mid-Day Session,2018-10-22 12:39:00-04:00,AVEO,neutral
115046.0,30 Stocks Moving In Monday's Pre-Market Session,2018-10-22 08:05:00-04:00,AVEO,neutral
115047.0,"UPDATE: AVEO, EUSA Say 'Tivozanib-Nivolumab Combination Continues to Demonstrate Favorable Efficacy and Safety'",2018-10-22 07:06:00-04:00,AVEO,positive
115048.0,"AVEO Oncology, EUSA Pharma Offer Updated Interim Results From Phase 2 Portion Of TiNivo Study In Renal Cell Carcinoma",2018-10-22 07:06:00-04:00,AVEO,neutral
115049.0,"REMINDER: ESMO 2018 Event Continues Today, Clinical Updates Presented Today Include: CytomX Therapeutics, Mirati Therapeutics, Merck, NuCana, Protagonist Therapeutics, SELLAS Life Sciences, Epizyme, Kura Oncology, Intra-Cellular Therapies, and AVEO Pharma",2018-10-22 05:56:00-04:00,AVEO,neutral
115050.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,AVEO,neutral
115051.0,"Benzinga Pro's Top 10 Most-Searched Tickers For The Morning Of Mon., Oct. 15, 2018",2018-10-15 10:42:00-04:00,AVEO,positive
115052.0,UPDATE: AVEO Sees Topline Results For TIVO-3 Trial In ~6 Weeks,2018-10-01 07:01:00-04:00,AVEO,neutral
115053.0,AVEO Oncology Reports Initiation Of Topline Analysis Of Phase 3 TIVO-3 Trial,2018-10-01 07:01:00-04:00,AVEO,neutral
115054.0,41 Biggest Movers From Yesterday,2018-09-27 05:01:00-04:00,AVEO,neutral
115055.0,30 Stocks Moving In Wednesday's Mid-Day Session,2018-09-26 12:32:00-04:00,AVEO,neutral
115056.0,Mid-Morning Market Update: Markets Edge Higher; CarMax Tops Q2 Expectations,2018-09-26 10:13:00-04:00,AVEO,positive
115057.0,51 Biggest Movers From Yesterday,2018-09-26 05:17:00-04:00,AVEO,neutral
115058.0,AVEO Prices 2.5M Share Offering At $2.26/Share,2018-08-17 09:16:00-04:00,AVEO,positive
115059.0,"The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns",2018-08-17 08:15:00-04:00,AVEO,negative
115060.0,23 Stocks Moving In Friday's Pre-Market Session,2018-08-17 08:02:00-04:00,AVEO,neutral
115061.0,"Benzinga's Top Upgrades, Downgrades For August 16, 2018",2018-08-16 08:54:00-04:00,AVEO,positive
115062.0,"H.C. Wainwright Initiates Coverage On AVEO Pharmaceuticals with Buy Rating, Announces $6.50 Price Target",2018-08-16 07:07:00-04:00,AVEO,neutral
115063.0,AVEO Oncology Announces the China National Drug Administration Accepted the Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer,2018-08-14 08:05:00-04:00,AVEO,negative
115064.0,"AVEO Pharmaceuticals Q2 EPS $(0.06), Inline, Sales $433K Miss $1.35M Estimate",2018-08-07 17:19:00-04:00,AVEO,negative
115065.0,38 Biggest Movers From Yesterday,2018-07-24 04:06:00-04:00,AVEO,neutral
115066.0,34 Stocks Moving In Monday's Mid-Day Session,2018-07-23 12:42:00-04:00,AVEO,neutral
115067.0,"Benzinga's Biggest Movers For The Week Of July 16, 2018",2018-07-20 16:08:00-04:00,AVEO,neutral
115068.0,UPDATE: AVEO Says Co. 'plans to announce when 255 PFS events have occurred and the topline data analysis for the trial has been initiated',2018-07-19 06:37:00-04:00,AVEO,neutral
115069.0,UPDATE: AVEO Says PFS Event Count Is 243,2018-07-19 06:37:00-04:00,AVEO,neutral
115070.0,"UPDATE: AVEO Sees Reporting Topline Results From TIVO-3 Study In Q4'18; Change In Guidance From Q3'18 ' is the result of PFS events occurring slower than forecasted, combined with ten patients being removed or 'censored' from the PFS event'",2018-07-19 06:36:00-04:00,AVEO,neutral
115071.0,AVEO Oncology Issues Statement Related To Revised TIVO-3 Trial Guidance,2018-07-19 06:36:00-04:00,AVEO,neutral
115072.0,51 Biggest Movers From Yesterday,2018-07-19 04:27:00-04:00,AVEO,neutral
115073.0,38 Biggest Movers From Yesterday,2018-07-18 05:47:00-04:00,AVEO,neutral
115074.0,28 Stocks Moving In Tuesday's Mid-Day Session,2018-07-17 12:32:00-04:00,AVEO,neutral
115075.0,22 Stocks Moving In Tuesday's Pre-Market Session,2018-07-17 08:11:00-04:00,AVEO,neutral
115076.0,4 Stocks Moving In Monday's After-Hours Session,2018-07-16 17:01:00-04:00,AVEO,neutral
115077.0,"Aveo Pharma 8-K Shows Warrant Deal With Computershare, Computershare Trust For Purchase Of 2M Shares Of Common Stock Related To Terms Of Stipulation Of Settlement OF Securities Class Action Suit",2018-07-16 16:38:00-04:00,AVEO,positive
115078.0,"AVEO Pharmaceuticals Received  Notice From Novartis On Jun. 29th Of A Termination Of The AV-380 License Agreement Dated August 13, 2015; Termination Will Be Effective Aug. 28 And Will Not Impact Co.'s Cash Guidance",2018-07-03 07:45:00-04:00,AVEO,positive
115079.0,"'This observation about delayed trials is often true. Also, hard to get excited about another TKI in kidney cancer. $AVEO so late to market.'-STAT's Adam Feuerstein Tweets",2018-05-08 09:13:00-04:00,AVEO,negative
115080.0,AVEO Pharma Says $27M In Cash Resources Will Allow Planned Operations To Be Funded Into Q1'19,2018-05-08 07:50:00-04:00,AVEO,positive
115081.0,"AVEO Pharmaceuticals Q1 EPS $(0.08) Misses $(0.07) Estimate, Sales $1.03M Miss $1.65M Estimate",2018-05-08 07:16:00-04:00,AVEO,negative
115082.0,38 Biggest Movers From Yesterday,2018-04-12 04:42:00-04:00,AVEO,neutral
115083.0,28 Stocks Moving In Wednesday's Mid-Day Session,2018-04-11 12:17:00-04:00,AVEO,neutral
115084.0,20 Stocks Moving In Wednesday's Pre-Market Session,2018-04-11 08:07:00-04:00,AVEO,neutral
115085.0,24 Stocks Moving In Friday's Mid-Day Session,2018-04-06 12:26:00-04:00,AVEO,neutral
115086.0,34 Biggest Movers From Yesterday,2018-04-06 04:21:00-04:00,AVEO,neutral
115087.0,"AVEO Oncology Reports Publication Of Long-Term Follow-Up Results From Study 902 In EJOC: Showed 161 Patients With aRCC Received Tivozanib, Activity Compares Favorably",2018-03-21 16:06:00-04:00,AVEO,positive
115088.0,AVEO Option Alert: Jul 20 $5 Calls Sweep (7) at the Ask: 1169 @ $0.351 vs 5535 OI; Earnings 5/3 Before Open [est] Ref=$2.88,2018-03-14 12:35:00-04:00,AVEO,positive
115089.0,"AVEO Reports Q4 EPS $(0.08) vs $(0.03) Est., Sales $82K vs $1.25M Est.",2018-03-13 07:06:00-04:00,AVEO,neutral
115090.0,AVEO Option Alert: Jul 20 $5 Calls at the Ask: 1597 @ $0.35 vs 922 OI; Earnings 5/3 Before Open [est] Ref=$2.825,2018-03-06 12:13:00-05:00,AVEO,positive
115091.0,25 Stocks Moving In Monday's Pre-Market Session,2018-02-12 08:06:00-05:00,AVEO,neutral
115092.0,"AVEO Oncology Announces the UK's National Institute for Health and Care Excellence Has Published a Final Appraisal Determination Recommending FOTIVDA, Triggers a $2M Milestone Payment From EUSA",2018-02-12 07:05:00-05:00,AVEO,positive
115093.0,"AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA, Recommendation Triggers $2M Milestone Payment from EUSA to AVEO",2018-02-12 07:02:00-05:00,AVEO,positive
115094.0,AVEO Oncology and EUSA Pharma Announce Encouraging Preliminary Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma Data Presented at #ASCO2018,2018-02-11 07:40:00-05:00,AVEO,positive
115095.0,19 Biotech Stocks With Clinical Trial Outcomes In February,2018-02-08 16:41:00-05:00,AVEO,neutral
115096.0,AVEO Option Alert: Feb 16 $3 Puts Sweep (10) at the Ask: 1000 @ $0.6 vs 102 OI; Ref=$2.865,2017-12-29 12:57:00-05:00,AVEO,positive
115097.0,"UPDATE: AVEO Says Mgmt. Agreed For Levine, Windham To Cause Certain Of Co.'s, Individual Defendants' Insurance Carriers To Provide The Class With Cash Payment Of $15M",2017-12-26 17:41:00-05:00,AVEO,positive
115098.0,"AVEO Pharma 8-K Shows Co. Entered Binding Memorandum Of Understanding With Class Representatives Bob Levine, William Windham Related To Settlement Of Securities Class Action Suit",2017-12-26 17:40:00-05:00,AVEO,positive
115099.0,The Companies That Led 2017's Biotech Rally,2017-12-22 09:50:00-05:00,AVEO,neutral
115100.0,Aveo Pharma Option Alert: Apr 20 $4 Calls at the Bid: 7039 @ $0.35 vs 801 OI; Ref=$2.91,2017-12-11 10:20:00-05:00,AVEO,positive
115101.0,AVEO Oncology Gives Updates on its Tivozanib and Ficlatuzumab Programs,2017-12-07 07:16:00-05:00,AVEO,neutral
115102.0,Aveo Pharmaceuticals Files For $200M Mixed Shelf Offering,2017-11-30 17:44:00-05:00,AVEO,neutral
115103.0,"EUSA Pharma, AVEO Oncology Announce the First Commercial Launch of FOTIVDA in EU",2017-11-15 04:28:00-05:00,AVEO,neutral
115104.0,"Hearing B. Riley Initiated Shares of Aveo Oncology With A Buy Rating, $5 PT",2017-11-13 08:57:00-05:00,AVEO,positive
115105.0,"AVEO Q3 EPS $(0.22) vs $(0.05) Est., Sales $4.6M vs $5.5M Est.",2017-11-07 07:50:00-05:00,AVEO,neutral
115106.0,"AVEO Reports Q3 EPS $(0.22) vs $(0.05) Est., Sales $4.61M vs $5.5M Est.",2017-11-07 07:26:00-05:00,AVEO,neutral
115107.0,40 Biggest Movers From Yesterday,2017-11-07 04:50:00-05:00,AVEO,neutral
115108.0,31 Stocks Moving In Monday's Mid-Day Session,2017-11-06 12:45:00-05:00,AVEO,neutral
115109.0,30 Stocks Moving In Monday's Pre-Market Session,2017-11-06 08:06:00-05:00,AVEO,neutral
115110.0,"AVEO Oncology, EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma",2017-11-06 04:41:00-05:00,AVEO,positive
115111.0,32 Biggest Movers From Yesterday,2017-10-18 03:53:00-04:00,AVEO,neutral
115112.0,30 Stocks Moving In Tuesday's Mid-Day Session,2017-10-17 12:33:00-04:00,AVEO,neutral
115113.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-10-10 08:08:00-04:00,AVEO,neutral
115114.0,"Seaport Global Initiates Coverage On AVEO Pharmaceuticals with Buy Rating, Announces $7.00 Price Target",2017-10-06 09:55:00-04:00,AVEO,neutral
115115.0,25 Stocks Moving In Friday's Pre-Market Session,2017-10-06 08:14:00-04:00,AVEO,neutral
115116.0,Aveo Pharmaceuticals Shares Up 2.53% After-hours After Co. Reports Completion of TIVO -3 Study Futility Analysis With No Changes To Protocol,2017-10-05 17:42:00-04:00,AVEO,neutral
115117.0,4 Breakout Biotech And Tech Charts To Watch,2017-10-05 12:33:00-04:00,AVEO,neutral
115118.0,The Street Has Finally Recognized The Exelixis Clinical Program Potential,2017-09-22 13:13:00-04:00,AVEO,neutral
115119.0,28 Stocks Moving In Wednesday's Pre-Market Session,2017-09-20 08:08:00-04:00,AVEO,neutral
115120.0,AVEO Oncology Phase 1/2 TiNivo Study Triggers $2M Milestone Payment,2017-09-20 07:16:00-04:00,AVEO,neutral
115121.0,AVEO Oncology Announces Receipt of $4M R&D Payment from EUSA Pharma and $0.5M Milestone Payment from CANbridge,2017-09-13 07:06:00-04:00,AVEO,neutral
115122.0,AVEO Pharma Shares Spike ~$0.08 Over Last Few Mins. As Traders Circulate Report From UK 'Takeover chatter of AVEO Pharamaceutics'; BZ NOTE: Co. Name Used In Title Of Report Is Different Than Co.'s Name 'AVEO Pharmaceuticals',2017-09-07 10:19:00-04:00,AVEO,positive
115123.0,Aveo Drops to Low of $3.11 on Volume,2017-08-29 14:08:00-04:00,AVEO,negative
115124.0,25 Stocks Moving In Monday's Pre-Market Session,2017-08-28 08:16:00-04:00,AVEO,neutral
115125.0,AVEO Oncology's FOTIVDA Approved in the EU for Treatment of Advanced Renal Cell Carcinoma,2017-08-28 06:18:00-04:00,AVEO,positive
115126.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-08-15 08:24:00-04:00,AVEO,neutral
115127.0,AVEO Pharma Shares Tick To Session Highs Up 5.5% As Seeing Notable Block Trade Over Last Few Mins: 1.1M Shares At $3.025/Share,2017-08-14 10:15:00-04:00,AVEO,positive
115128.0,"AVEO Q2 EPS $(0.30) vs $(0.09) Est., Sales $351K vs $1M Est.",2017-08-09 07:09:00-04:00,AVEO,neutral
115129.0,10 Biggest Mid-Day Losers For Wednesday,2017-07-12 12:50:00-04:00,AVEO,negative
115130.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-07-12 08:06:00-04:00,AVEO,neutral
115131.0,12 Biggest Mid-Day Losers For Tuesday,2017-07-11 13:13:00-04:00,AVEO,negative
115132.0,20 Stocks Moving In Tuesday's Pre-Market Session,2017-07-11 08:10:00-04:00,AVEO,neutral
115133.0,10 Biggest Mid-Day Gainers For Monday,2017-07-10 12:26:00-04:00,AVEO,neutral
115134.0,Mid-Day Market Update: ClubCorp Surges Following Acquisition By Apollo Global; Cincinnati Bell Shares Drop,2017-07-10 12:04:00-04:00,AVEO,neutral
115135.0,Mid-Morning Market Update: Markets Mostly Flat; Helen of Troy Profit Beats Views,2017-07-10 10:13:00-04:00,AVEO,positive
115136.0,AVEO Pharmaceuticals Shares Up 10% In Pre-Market Ahead Of Regulatory Decision From European Commission On Tivozanib Drug,2017-07-10 08:38:00-04:00,AVEO,positive
115137.0,22 Stocks Moving In Monday's Pre-Market Session,2017-07-10 08:24:00-04:00,AVEO,neutral
115138.0,12 Biggest Mid-Day Gainers For Friday,2017-07-07 12:30:00-04:00,AVEO,neutral
115139.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-06-29 08:36:00-04:00,AVEO,neutral
115140.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-06-27 08:21:00-04:00,AVEO,neutral
115141.0,Aveo +10.77% Premarket @$2.16,2017-06-27 07:15:00-04:00,AVEO,neutral
115142.0,Mid-Afternoon Market Update: Portola Climbs On FDA Approval For Bevyxxa; American Software Shares Plunge,2017-06-23 14:30:00-04:00,AVEO,positive
115143.0,15 Biggest Mid-Day Gainers For Friday,2017-06-23 12:26:00-04:00,AVEO,neutral
115144.0,Mid-Day Market Update: Bed Bath & Beyond Drops Following Disappointing Earnings; Synchronoss Technologies Shares Surge,2017-06-23 12:03:00-04:00,AVEO,negative
115146.0,"PiperJaffray Out Positive On AVEO, Says EU Approval Likely By August And Increases Price Target to $2",2017-06-23 10:21:00-04:00,AVEO,positive
115147.0,Mid-Morning Market Update: Markets Mostly Flat; BlackBerry Sales Miss Views,2017-06-23 10:15:00-04:00,AVEO,negative
115148.0,20 Stocks Moving In Friday's Pre-Market Session,2017-06-23 08:19:00-04:00,AVEO,neutral
115149.0,AVEO Oncology Reports Positive CHMP Opinion for Tivozanib,2017-06-23 08:02:00-04:00,AVEO,positive
115150.0,AVEO Oncology Reports Positive CHMP Opinion For Tivozanib For Treatment Of Advanced Renal Cell Carcinoma,2017-06-23 08:02:00-04:00,AVEO,positive
115151.0,Adam Feuerstein Tweets: $AVEO +36% on positive CHMP opinion. Not sure how much tivo will be used but it's a nice turnaround story.,2017-06-23 07:53:00-04:00,AVEO,positive
115153.0,Aveo Pharma Expecting Phase 3 Topline Data in Q1 2018,2017-06-20 07:07:00-04:00,AVEO,neutral
115155.0,AVEO Oncology Says Phase 1/2 TiNivo Trial Has Progressed to Phase 2,2017-06-08 07:03:00-04:00,AVEO,neutral
115156.0,"AVEO Oncology and Biodesix Announce Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017",2017-06-05 14:18:00-04:00,AVEO,neutral
115157.0,AVEO Oncology Announces Matthew Dallas CFO,2017-05-16 07:08:00-04:00,AVEO,neutral
115158.0,AVEO Oncology Announces Receipt of USPTO Notice of Allowance for to AV-353,2017-05-08 07:17:00-04:00,AVEO,neutral
115159.0,"AVEO Pharma Reports Q1 EPS $(0.12), Inline, Collaboration, Licensing Sales $2.532M",2017-05-04 07:12:00-04:00,AVEO,neutral
115160.0,AVEO Reports Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues,2017-04-13 08:04:00-04:00,AVEO,positive
115161.0,AVEO Pharma Prices $15M Common Stock Offering of 30M Shares at $0.50/Share,2017-03-28 09:10:00-04:00,AVEO,positive
115162.0,AVEO Pharma Announces Proposed Offering to Fund Phase 3 Trial,2017-03-28 06:35:00-04:00,AVEO,neutral
115163.0,Aveo Pharmaceuticals Has Identified Conditions and Events That Raise Substantial Doubt About Ability To Continue As Going Concern,2017-03-22 16:24:00-04:00,AVEO,positive
115164.0,"AVEO Reports Q4 EPS $(0.07) vs. $(0.11) Est., Sales $127K vs. $100K Est.",2017-03-22 16:07:00-04:00,AVEO,neutral
115165.0,"AVEO Oncology Reports First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib, Opdivo in Advanced RCC",2017-03-22 07:09:00-04:00,AVEO,positive
115166.0,AVEO Reports First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo in Advanced RCC,2017-03-22 07:01:00-04:00,AVEO,positive
115167.0,AVEO Reports TIVO-3 Passes The First Safety Monitoring Committee Safety Review,2017-02-23 07:15:00-05:00,AVEO,positive
115168.0,AVEO Announces Pivotal TIVO-3 Trial Enrollment Proceeding Substantially Ahead of Schedule; Enrollment Completion Expected in June,2017-02-09 16:23:00-05:00,AVEO,neutral
115169.0,8-K from AVEO Pharma Shows Co. Received Deficiency Letter from Nasdaq Related to Non-Compliance of $50M Market Value Requirement,2017-01-12 16:09:00-05:00,AVEO,positive
115170.0,AVEO Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Tivozanib in Renal Cell Carcinoma - BSW  28-Nov-2016 07:00,2016-11-28 07:18:00-05:00,AVEO,neutral
115171.0,"AVEO Oncology Reports Q3 EPS $(0.07) vs. Est. $(0.12), Rev. $992K vs. Est. $100K",2016-11-04 07:15:00-04:00,AVEO,neutral
115172.0,10 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-20 06:50:00-04:00,AVEO,neutral
115173.0,AVEO Oncology Reports Proposed Settlement and Settlement Hearing in 2014 Stockholder Litigation,2016-09-30 16:01:00-04:00,AVEO,negative
115174.0,AVEO Pharmaceuticals Announces Discontinuation of the FOCAL Study Evaluating Ficlatuzumab,2016-09-12 06:08:00-04:00,AVEO,neutral
115175.0,A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Empire State Manufacturing Index,2016-08-15 07:58:00-04:00,AVEO,neutral
115176.0,AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb's Opdivo\ in Advanced Renal Cell Carcinoma,2016-08-15 07:01:00-04:00,AVEO,positive
115177.0,AVEO Oncology Reports Q2 EPS $(0.13) vs. Est. $(0.14),2016-08-04 07:10:00-04:00,AVEO,neutral
115178.0,S-3 from Aveo Pharma Shows Registration for $38.58M Common Stock Offering via Selling Holders,2016-06-15 17:31:00-04:00,AVEO,neutral
115179.0,"Growth Equity Opportunities IV, LLC Reports 29.6% Stake in Aveo Pharmaceuticals in 13D",2016-05-31 17:27:00-04:00,AVEO,positive
115180.0,"AVEO Reports Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma, Expected To Enroll 322 Patients",2016-05-26 07:04:00-04:00,AVEO,neutral
115181.0,Piper Jaffray Initiates Coverage on AVEO Pharmaceuticals at Overweight,2016-05-19 06:44:00-04:00,AVEO,negative
115182.0,"AVEO Oncology Closes Private Placement, Amends Terms of Loan to Provide $10M in Funding",2016-05-18 07:03:00-04:00,AVEO,neutral
115183.0,AVEO Oncology Reports $17M Private Placement,2016-05-13 09:00:00-04:00,AVEO,neutral
115184.0,"AVEO Oncology Reports Q1 EPS $(0.13) vs $(0.12) Est., Sales $1.2M vs $550K Est.",2016-05-10 16:34:00-04:00,AVEO,neutral
115185.0,"AVEO Oncology Reports Q1 EPS $(0.13) vs. Est. $(0.12), Rev. $1.20M vs. Est. $550K",2016-05-10 16:16:00-04:00,AVEO,neutral
115186.0,AVEO Oncology Reports Filing of Provisional Patent Apps for AV-353 for PAH,2016-05-02 07:18:00-04:00,AVEO,neutral
115187.0,UPDATE: Some Traders Attributing Upside in Aveo to GenomeWeb Report from Yesterday Biodesix Received Two Positive Coverage Decisions for Veristrat,2016-04-05 11:08:00-04:00,AVEO,positive
115188.0,Aveo Shares Shares Spike to $1.00; May be Attributed to Report on Veristrat Coverage,2016-04-05 11:06:00-04:00,AVEO,positive
115189.0,"Aveo Shares Spike Higher Over Last Few Mins, Now Up 6.3%",2016-04-05 11:06:00-04:00,AVEO,positive
115190.0,FBR Capital Initiates Coverage on AVEO Pharmaceuticals at Outperform,2016-03-30 07:12:00-04:00,AVEO,neutral
115191.0,Aveo Will Pay $4M to Settle with SEC,2016-03-29 12:14:00-04:00,AVEO,negative
115192.0,Hearing SEC Has Said Aveo Pharm Has Misled Investors About New Drug's Status with FDA,2016-03-29 12:12:00-04:00,AVEO,neutral
115193.0,"Aveo Pharma Shares Selloff, Traders Attribute Move To Reports Co May Pay $4M To SEC To Settle Allegations Of Misleading Investors",2016-03-29 11:58:00-04:00,AVEO,negative
115194.0,Aveo Announces EMA Validates MAA for Tivozanib as First-line Treatment for Advanced RCC -8K,2016-03-24 09:48:00-04:00,AVEO,positive
115195.0,"AVEO Oncology Reports Quarter Ended EPS $(0.11) vs. Est. $(0.04), Rev. $3.59M vs. Est. $100K",2016-03-15 07:30:00-04:00,AVEO,neutral
115196.0,Aveo Pharma Q4 EPS (0.11) vs ($0.04) est,2016-03-15 06:23:00-04:00,AVEO,neutral
115197.0,"EUSA Pharma, AVEO Announce Submission of Marketing Authorization Application to EMA for Tivozanib in Advanced Renal Cell Carcinoma",2016-03-01 04:56:00-05:00,AVEO,positive
115198.0,AVEO Announces Acceptance of Registration Dossier for Tivozanib in RCC by the Ministry of Health of the Russian Federation,2016-02-22 07:03:00-05:00,AVEO,positive
115199.0,EXCLUSIVE: AVEO CEO Explains How New Partnership Will Address $500 Million Opportunity Overseas,2015-12-21 13:39:00-05:00,AVEO,positive
115200.0,Mid-Morning Market Update: Markets Open Higher; Neogen Earnings Miss View,2015-12-21 09:55:00-05:00,AVEO,negative
115201.0,AVEO and EUSA Pharma Announce Exclusive Licensing Agreement for Tivozanib in Europe,2015-12-21 06:30:00-05:00,AVEO,positive
115202.0,AVEO Oncology Announces Chairman Tuan Ha-Ngoc Steps Down,2015-11-09 06:15:00-05:00,AVEO,neutral
115203.0,Repeat Performance In Aveo Pharmaceuticals After Spike In Price,2015-08-17 13:34:00-04:00,AVEO,neutral
115204.0,Morning Market Gainers,2015-08-17 09:45:00-04:00,AVEO,neutral
115205.0,Benzinga's Top #PreMarket Gainers,2015-08-17 08:08:00-04:00,AVEO,positive
115206.0,US Stock Futures Flat Ahead Of Housing Data,2015-08-17 07:29:00-04:00,AVEO,neutral
115207.0,UPDATE: AVEO +107% Premarket Following Announcement of Licensing Deal With Novartis,2015-08-17 06:53:00-04:00,AVEO,neutral
115208.0,Aveo Shares Rise 28% Premaket Following Announcement of Licensing Agreement With Novartis,2015-08-17 06:07:00-04:00,AVEO,positive
115209.0,"UPDATE: AVEO to Receive $15M Upfront Payment from Novatis, Up to $311M in Milestone Payments",2015-08-17 06:06:00-04:00,AVEO,neutral
115210.0,"AVEO Announces Exclusive Worldwide License Agreement for, Development, Commercialization of AV-380 and Related Antibodies",2015-08-17 06:02:00-04:00,AVEO,positive
115211.0,This Week's First IPO: Global Blood Therapeutics Developing Drugs For Diseases Affecting Few,2015-08-13 09:23:00-04:00,AVEO,neutral
115212.0,Aveo Pharma Q2 EPS -$0.10 vs -$0.20 est,2015-08-10 07:03:00-04:00,AVEO,neutral
115213.0,Morning Market Losers,2015-06-12 10:00:00-04:00,AVEO,negative
115214.0,"FDA On AVEO's Tivozanib, 'at present, ""insufficient data exists to determine the appropriateness of this [NRP-1 low] subgroup"" for the proposed phase 3 study'",2015-06-11 16:32:00-04:00,AVEO,neutral
115215.0,AVEO Gives FDA Update For Tivozanib In Colorectal Cancer,2015-06-11 16:31:00-04:00,AVEO,negative
115216.0,Mid-Day Market Update: Sigma Designs Surges On Upbeat Results; Boulder Brands Shares Drop,2015-06-10 13:05:00-04:00,AVEO,neutral
115217.0,Morning Market Gainers,2015-06-04 09:42:00-04:00,AVEO,neutral
115218.0,Shares of Aveo Rise 32% Premarket Following Announcement of Support from Rapporteur and co-Rapporteur for Filing of Marketing Authorization Application for Tivozanib,2015-06-04 08:28:00-04:00,AVEO,positive
115219.0,Benzinga's Top #PreMarket Gainers,2015-06-04 08:16:00-04:00,AVEO,positive
115220.0,AVEO Receives European Regulatory Guidance Regarding Potential Marketing Authorization Application for Tivozanib,2015-06-03 19:31:00-04:00,AVEO,neutral
115221.0,Morning Market Losers,2015-06-03 09:52:00-04:00,AVEO,negative
115222.0,Benzinga's Top #PreMarket Losers,2015-06-03 08:17:00-04:00,AVEO,negative
115223.0,Morning Market Gainers,2015-06-02 09:42:00-04:00,AVEO,neutral
115224.0,Benzinga's Top #PreMarket Gainers,2015-06-02 08:07:00-04:00,AVEO,positive
115225.0,Aveo Shares Rise 16% Premarket Following Monday Announcement of Biodesix Receiving Positive Coverage from Cigna for VeriStrat Test,2015-06-02 07:22:00-04:00,AVEO,positive
115226.0,"PVH Corp, Atlantic Power, Carlyle Group Lead Monday's After-Hours Movers",2015-06-01 17:54:00-04:00,AVEO,neutral
115227.0,Biodesix Receives Positive Coverage from Cigna for VeriStrat Test,2015-06-01 15:31:00-04:00,AVEO,positive
115228.0,Aveo Shares Spike Higher,2015-06-01 15:24:00-04:00,AVEO,positive
115229.0,Morning Market Gainers,2015-05-22 09:46:00-04:00,AVEO,neutral
115230.0,Benzinga's Top #PreMarket Gainers,2015-05-22 08:20:00-04:00,AVEO,positive
115231.0,"BlackBerry, Monro Muffler, Valeant In Thursday's After-Hours Movers",2015-05-21 18:47:00-04:00,AVEO,neutral
115232.0,What's Up With The Delayed Reaction In Aveo Pharmaceuticals?,2015-05-21 12:01:00-04:00,AVEO,negative
115233.0,Aveo Pharmaceuticals Shares Rise 110% Thursday Following Wednesday's Announced Results of TIVO-1 Study,2015-05-21 10:47:00-04:00,AVEO,positive
115234.0,Stocks Hitting 52-Week Highs,2015-05-21 10:21:00-04:00,AVEO,neutral
115235.0,Morning Market Gainers,2015-05-21 09:49:00-04:00,AVEO,neutral
115236.0,Morning Market Gainers,2015-05-20 09:43:00-04:00,AVEO,neutral
115237.0,"AVEO Reports Presentation of Final Results of Extension Study 902, FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma",2015-05-20 07:03:00-04:00,AVEO,neutral
115238.0,Aveo Pharmaceuticals Files Up to $100M Debt Securities Shelf,2015-05-07 06:30:00-04:00,AVEO,negative
115239.0,Aveo Pharma Q1 EPS -$0.21 vs -$0.25 est,2015-05-07 06:28:00-04:00,AVEO,neutral
115240.0,AVEO Names Keith S. Ehrlich as CFO,2015-04-22 07:07:00-04:00,AVEO,neutral
115241.0,AVEO Oncology Names Keith Ehrlich CFO,2015-04-22 07:00:00-04:00,AVEO,neutral
115242.0,AVEO Oncology Presents AV-380 Preclinical Data in Cancer Associated Cachexia at AACR,2015-04-20 07:05:00-04:00,AVEO,negative
115243.0,Morning Market Gainers,2015-03-09 09:43:00-04:00,AVEO,neutral
115244.0,RBC Capital Upgrades AVEO Pharmaceuticals To Sector Perform,2015-03-09 09:35:00-04:00,AVEO,neutral
115245.0,Benzinga's Top Upgrades,2015-03-09 09:02:00-04:00,AVEO,positive
115246.0,UPDATE: RBC Capital Markets Upgrades AVEO Pharmaceuticals On Progress In Multiple Areas,2015-03-09 08:38:00-04:00,AVEO,positive
115247.0,"RBC Capital Upgrades AVEO Pharmaceuticals to Sector Perform, Raises PT to $3.00",2015-03-09 05:52:00-04:00,AVEO,neutral
115248.0,AVEO Pharmaceuticals Soars On Phase II Results Vs. Avastin,2015-03-06 12:51:00-05:00,AVEO,neutral
115249.0,Morning Market Gainers,2015-03-06 09:44:00-05:00,AVEO,neutral
115250.0,Benzinga's Top #PreMarket Gainers,2015-03-06 08:07:00-05:00,AVEO,positive
115251.0,UPDATE: Aveo Oncology Shares Rise 26% Premarket on Positive Phase 2 Tivozanib Results,2015-03-06 07:27:00-05:00,AVEO,positive
115252.0,Aveo Oncology Q4 EPS -$0.27 vs -$0.21,2015-03-06 06:06:00-05:00,AVEO,neutral
115253.0,"Klarman-Founded Baupost Group Increases Stake In eBay, Trims Micron and Citigroup In Q4",2015-02-14 19:49:00-05:00,AVEO,neutral
115254.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4,2015-01-13 11:34:00-05:00,AVEO,neutral
115255.0,Amended 13G Filing from Klarman's Baupost Group Shows Liquidated Position; Had Previously Shown 7.33% Stake as of Sept. 30,2015-01-09 16:38:00-05:00,AVEO,neutral
115256.0,"US Stock Futures Surge Ahead Of ADP Report, Fed Minutes",2015-01-07 07:06:00-05:00,AVEO,neutral
115257.0,"AVEO Names Michael P. Bailey as President, CEO; Tuan Ha-Ngoc to Become Chairman",2015-01-07 06:31:00-05:00,AVEO,neutral
115258.0,"8-K from Aveo Pharma Shows Co. Received NASDAQ Deficiency Letter Related to Bid Price; Co. Has Until Jun. 29, 2015 to Regain Compliance",2014-12-30 07:26:00-05:00,AVEO,neutral
115259.0,US Stock Futures Slightly Higher; Dollar Surges Against Yen,2014-11-11 07:04:00-05:00,AVEO,neutral
115260.0,AVEO Enters into Research And Exclusive Option Agreement With Ophthotech For Tivozanib (VEGF inhibitor) For The Treatment Of Ocular Diseases,2014-11-11 06:46:00-05:00,AVEO,positive
115261.0,AVEO Oncology Presents Results from Phase 2 Clinical Studies of Tivozanib at ESMO 2014 Congress ,2014-09-29 06:56:00-04:00,AVEO,neutral
115262.0,"AVEO, Biodesix Present Exploratory Analysis of VeriStrat-Selected Patients with NSCLC in Phase 2 Study of Ficlatuzumab at ESMO ",2014-09-29 06:22:00-04:00,AVEO,neutral
115263.0,AVEO Oncology Announces Lease Termination And Amendment To Debt Financing Facility,2014-09-26 07:01:00-04:00,AVEO,negative
115264.0,"AVEO Pharmaceuticals, Inc. Reports Q2 EPS of $(0.35) vs $(0.44) Est",2014-08-11 16:30:00-04:00,AVEO,neutral
115265.0,"Stocks To Watch For June 10, 2014",2014-06-10 07:44:00-04:00,AVEO,neutral
115266.0,"Stocks To Watch For June 06, 2014",2014-06-06 07:39:00-04:00,AVEO,neutral
115267.0,AVEO Oncology AV-203 Phase 1 Results Presented at ASCO Demonstrated Good Tolerability and Promising Early Signs of Activity,2014-05-31 15:06:00-04:00,AVEO,positive
115268.0,"AVEO Pharmaceuticals, Inc. Reports Q1 EPS of $(0.12) vs $(0.40) Est; Revenue of $15.30M vs $1.75M Est",2014-05-07 17:26:00-04:00,AVEO,neutral
115269.0,Morning Market Movers ,2014-04-10 09:42:00-04:00,AVEO,neutral
115270.0,"UPDATE: AVEO, Biodesix Announce Agreement to Co-Develop and Commercialize Ficlatuzumab  for Treatment of NSCLC ",2014-04-10 06:40:00-04:00,AVEO,positive
115271.0,"AVEO, Biodesix Partner to Co-Develop, Commercialize Ficlatuzumab with Companion Diagnostic to Treat NSCLC",2014-04-10 06:38:00-04:00,AVEO,positive
115272.0,Stocks Hitting 52-Week Lows,2014-04-07 10:35:00-04:00,AVEO,negative
115273.0,"AVEO Announces Deal with Biogen, Regains Global Rights to AV-203",2014-03-20 16:31:00-04:00,AVEO,neutral
115274.0,AVEO Pharma Says Chief Medical Officer Slichenmyer to Leave Co.,2014-03-13 15:23:00-04:00,AVEO,negative
115275.0,"AVEO Pharmaceuticals, Inc. Reports Q4 EPS of $(0.32) vs $(0.33) Est; Revenue of $323.0K vs $140.0K Est",2014-03-13 15:22:00-04:00,AVEO,neutral
115276.0,"Earnings Scheduled For March 13, 2014",2014-03-13 04:51:00-04:00,AVEO,neutral
115277.0,Benzinga Weekly Preview: Ukraine Tension Likely To Drive Markets,2014-03-07 16:11:00-05:00,AVEO,negative
115278.0,"AVEO,  Astellas to End Worldwide Collaboration on Tivozanib ",2014-02-14 05:36:00-05:00,AVEO,neutral
115279.0,AVEO Pharmaceuticals: Tivozanib Trial Discontinued Due to Low Patient Accrual,2014-01-30 06:35:00-05:00,AVEO,negative
115280.0,Stocks Hitting 52-Week Lows,2013-12-16 10:35:00-05:00,AVEO,negative
115281.0,"RBC Capital Downgrades AVEO Pharmaceuticals, Inc. to Underperform, Lowers PT to $2.00",2013-12-16 08:35:00-05:00,AVEO,negative
115282.0,Stocks Hitting 52-Week Lows,2013-12-13 10:15:00-05:00,AVEO,negative
115283.0,Morning Market Losers ,2013-12-13 10:09:00-05:00,AVEO,negative
115284.0,US Stock Futures Gain Ahead Of Producer Price Index,2013-12-13 07:07:00-05:00,AVEO,positive
115285.0,AVEO Says Tivozanib Trial in Colorectal Cancer Unlikely to Meet Primary Endpoint,2013-12-13 06:53:00-05:00,AVEO,negative
115286.0,Aveo Pharmaceuticals CFO David Johnston to Resign Effective December 30,2013-12-02 09:21:00-05:00,AVEO,positive
115287.0,"Stocks to Watch for November 04, 2013",2013-11-04 10:29:00-05:00,AVEO,neutral
115288.0,"Stocks to Watch for October 28, 2013",2013-10-28 10:07:00-04:00,AVEO,neutral
115289.0,"Stocks to Watch for October 25, 2013",2013-10-25 12:28:00-04:00,AVEO,neutral
115290.0,"AVEO Pharmaceuticals, Inc. Reports Q2 EPS of $(0.62) vs $(0.56) Est; Revenue of $324.0K vs $4.30M Est",2013-08-08 06:51:00-04:00,AVEO,neutral
115291.0,UPDATE: AVEO Pharmaceuticals Receives Subpoena from SEC,2013-07-11 16:36:00-04:00,AVEO,neutral
115292.0,AVEO Pharma Says SEC Requested Documents and Information on TIVOZANIB via Subpoena on July 3rd,2013-07-11 16:36:00-04:00,AVEO,neutral
115293.0,AVEO Receives CRL from FDA for Tivozanib New Drug Application in Renal Cell Carcinoma ,2013-06-10 06:33:00-04:00,AVEO,neutral
115294.0,AVEO Oncology Announces Strategic Restructuring ,2013-06-04 16:31:00-04:00,AVEO,neutral
115295.0,"UPDATE: Aveo COO to Resign, Announces $7.5-8.5M in Charges",2013-06-04 16:31:00-04:00,AVEO,negative
115296.0,"AVEO Oncology Announces Strategic Restructuring, to Cut 140 Jobs or 62% of Total Headcount",2013-06-04 16:31:00-04:00,AVEO,negative
115297.0,Benzinga's Top Pre-Market Losers,2013-05-28 08:12:00-04:00,AVEO,negative
115298.0,Aveo Pharma Says Astellas to No Longer Submit EMA App for RCC Path Tivozanib,2013-05-23 16:17:00-04:00,AVEO,negative
115299.0,"RBC Capital Downgrades AVEO Pharmaceuticals, Inc. to Sector Perform, Lowers PT to $6.00",2013-05-03 09:57:00-04:00,AVEO,negative
115300.0,"Stifel Nicolaus Upgrades AVEO Pharmaceuticals, Inc. to Hold",2013-05-03 09:56:00-04:00,AVEO,neutral
115301.0,UPDATE: Canaccord Genuity Downgrades AVEO Pharmaceuticals to Hold Following ODAC Meeting,2013-05-03 09:15:00-04:00,AVEO,neutral
115302.0,"Canaccord Genuity Downgrades AVEO Pharmaceuticals, Inc. to Hold, Lowq PT to $2.00",2013-05-03 06:46:00-04:00,AVEO,neutral
115303.0,"William Blair Downgrades AVEO Pharmaceuticals, Inc. to Market Perform",2013-05-02 14:37:00-04:00,AVEO,neutral
115304.0,"JP Morgan Downgrades AVEO Pharmaceuticals, Inc. to Neutral",2013-05-02 14:02:00-04:00,AVEO,positive
115305.0,"RBC's Butt Maintains Outperform on AVEO Following Negative Panel Ruling, Says Co. Will Need Another Phase 3 Trial, But Hasn't Yet Committed",2013-05-02 13:55:00-04:00,AVEO,negative
115306.0,"AVEO Pharma Shares Resume Following Breaker, Now Down 52%",2013-05-02 13:25:00-04:00,AVEO,positive
115307.0,"AVEO Halted on Circuit Breaker Immediately Upon Resuming, Now Down 57%",2013-05-02 13:20:00-04:00,AVEO,neutral
115308.0,Shares of AVEO to Resume Trading at 1:20PM EDt,2013-05-02 13:16:00-04:00,AVEO,positive
115309.0,"BMO Capital Downgrades AVEO Pharmaceuticals, Inc. to Underperform, Lowers PT to $1.00",2013-05-02 12:54:00-04:00,AVEO,negative
115310.0,"AVEO, Astellas Confirm Unfavorable Vote by FDA Oncologic Drug Advisory Committee on Tivozanib",2013-05-02 12:53:00-04:00,AVEO,neutral
115311.0,UPDATE: FDA Panel Votes 1-13 Aveo Drug's Risk Benefit is Favorable,2013-05-02 11:57:00-04:00,AVEO,positive
115312.0,Aveo Fails to Win FDA Panel Backing,2013-05-02 11:56:00-04:00,AVEO,positive
115313.0,AVEO Pharmaceuticals Halted for FDA Panel,2013-05-02 07:07:00-04:00,AVEO,neutral
115314.0,Illumina and Other Bargain Biotech Stocks Worth a Look Now,2013-05-01 12:57:00-04:00,AVEO,positive
115315.0,FDA Issues Review of Aveo/Astella's Tivozanib in Kidney Cancer Ahead of May 2nd Panel,2013-04-30 08:13:00-04:00,AVEO,negative
115316.0,"AVEO Pharmaceuticals, Inc. Reports Q1 EPS of $(0.69) vs $(0.72) Est",2013-04-29 06:36:00-04:00,AVEO,neutral
115317.0,"JMP Securities Initiates Coverage on AVEO Pharmaceuticals, Inc. at Market Perform",2013-04-02 08:52:00-04:00,AVEO,positive
115318.0,13 Drugs Pending FDA Approval in 2013,2013-03-26 13:19:00-04:00,AVEO,positive
115319.0,A Peek Into The Market Before The Trading Starts,2013-02-27 07:25:00-05:00,AVEO,neutral
115320.0,"AVEO, Astellas Announce FDA Advisory Committee to Review NDA for Tivozanib on May 2, 2013",2013-02-27 06:36:00-05:00,AVEO,neutral
115321.0,"Jefferies Maintains Hold on AVEO Pharmaceuticals, Inc., Lowers PT to $6.00",2013-02-14 07:11:00-05:00,AVEO,negative
115322.0,13-F Alert: Baupost Group Adds AIG Shares and Microsoft Call Options,2013-02-13 18:16:00-05:00,AVEO,positive
115323.0,"Mid-Morning Market Update: Markets Into the Green, Cliffs Falling on Secondary Offering",2013-02-13 10:33:00-05:00,AVEO,negative
115324.0,"AVEO Pharmaceuticals, Inc. Reports Q4 EPS of $(0.49) vs $(0.77) Est; Revenue of $15.53M vs $14.49M Est",2013-02-13 06:44:00-05:00,AVEO,neutral
115325.0,A Peek Into The Market Before The Trading Starts,2013-01-29 07:22:00-05:00,AVEO,neutral
115326.0,"AVEO, Astellas Announce Presentations of Tivozanib Clinical Data ",2013-01-29 06:51:00-05:00,AVEO,neutral
115327.0,AVEO Pharmaceuticals Closes Public Offering ,2013-01-24 06:56:00-05:00,AVEO,neutral
115328.0,AVEO Prices 6.7M Shares at $7.50/Share,2013-01-17 09:12:00-05:00,AVEO,positive
115329.0,Aveo Announces Common Stock Offering,2013-01-16 16:06:00-05:00,AVEO,neutral
115330.0,Aveo Announces Common Stock Offering,2013-01-16 16:06:00-05:00,AVEO,neutral
115331.0,A Peek Into The Market Before The Trading Starts,2012-11-28 07:20:00-05:00,AVEO,neutral
115332.0,"AVEO, Astellas Announce FDA Acceptance of NDA Filing for Tivozanib",2012-11-28 06:41:00-05:00,AVEO,positive
115333.0,UPDATE: Stifel Nicolaus Initiates AVEO Pharmaceuticals at Sell; Tivozanib Decision Likely Negative  ,2012-11-14 11:22:00-05:00,AVEO,negative
115334.0,Stifel Nicolaus Initiates Coverage on AVEO Pharmaceuticals at Sell,2012-11-14 08:12:00-05:00,AVEO,neutral
115335.0,"UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Aveo Pharmaceuticals",2012-10-31 11:30:00-04:00,AVEO,negative
115336.0,"Jefferies & Company Maintains AVEO Pharmaceuticals at Hold, Lowers PT from $11 to $9",2012-10-31 07:57:00-04:00,AVEO,negative
115337.0,AVEO  Oncology Announces Strategic Restructuring ,2012-10-30 06:44:00-04:00,AVEO,neutral
115338.0,"AVEO, Astellas Announce New Data from Phase 3 TIVO-1 Trial",2012-10-01 07:10:00-04:00,AVEO,neutral
115339.0,AVEO Presents Detailed Results of Exploratory Phase 2 Study Evaluating Ficlatuzumab in First-Line Patients with Advanced Non-small Cell Lung Cancer,2012-10-01 06:41:00-04:00,AVEO,negative
115340.0,AVEO and Astellas Announce Submission of New Drug Application for Tivozanib,2012-09-28 07:48:00-04:00,AVEO,neutral
115341.0,New Clinical Data on AVEO Oncology's Tivozanib and Ficlatuzumab to be Presented at ESMO 2012 Congress ,2012-09-20 06:39:00-04:00,AVEO,neutral
115342.0,UPDATE: Jefferies Downgrades Aveo Pharmaceuticals to Hold on Regulatory Risk  ,2012-08-03 10:50:00-04:00,AVEO,negative
115343.0,"Jefferies & Company Downgrades AVEO Pharmaceuticals from Buy to Hold, Lowers PT from $30 to $11",2012-08-03 05:52:00-04:00,AVEO,negative
115344.0,AVEO Pharmaceuticals Reports Q2 EPS $-0.68 vs $-0.89 Est; Revenues $1.88M vs $1.54M Est,2012-08-02 08:37:00-04:00,AVEO,neutral
115345.0,AVEO Pharmaceuticals Reports Q2 EPS $-0.68 vs $-0.89 Est; Revenues $1.88M vs $1.54M Est,2012-08-02 06:46:00-04:00,AVEO,neutral
115346.0,AVEO Pharmaceuticals Spiking Higher on Heavy Volume; Currently at $12.97,2012-06-04 15:53:00-04:00,AVEO,neutral
115347.0,AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer   ,2012-06-04 07:45:00-04:00,AVEO,negative
115348.0,From EArlier: AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC  ,2012-05-17 06:55:00-04:00,AVEO,positive
115349.0,"BMO Capital Markets Initiates Coverage on AVEO Pharmaceuticals at Market Perform, Announces PT of $13",2012-03-13 07:26:00-04:00,AVEO,neutral
115350.0,AVEO Pharmaceuticals Reports Q4 EPS $(0.58) vs $(0.61) Est; Revenues $1.1M vs $4.30M Est	 		,2012-02-14 06:48:00-05:00,AVEO,neutral
115351.0,Morgan Stanley Initiates Coverage on AVEO Pharmaceuticals at Equal-weight,2012-02-10 06:38:00-05:00,AVEO,neutral
115352.0,These 4 stocks I own could make big upward moves in 2012,2012-01-26 12:53:00-05:00,AVEO,neutral
115353.0,Jefferies' Aveo Pharmaceuticals Management Remains Confident in Differentiation From Inlyta,2012-01-17 09:43:00-05:00,AVEO,positive
115354.0,"End-of-Day Market Summary for January 3, 2012",2012-01-03 16:17:00-05:00,AVEO,neutral
115355.0,Afternoon Movers; Markets Moved Higher,2012-01-03 16:04:00-05:00,AVEO,neutral
115356.0,AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib ,2012-01-03 06:55:00-05:00,AVEO,positive
115357.0,AVEO Announces Patient Enrollment in Phase 2 Clinical Trial of Tivozanib in Combination with mFOLFOX6 in Patients with Advanced Colorectal Cancer   ,2011-12-22 06:56:00-05:00,AVEO,negative
115358.0,AVEO Pharmaceuticals and Boehringer Ingelheim Announce Manufacturing Agreement for Ficlatuzumab,2011-12-01 08:35:00-05:00,AVEO,positive
115359.0,Canaccord Maintains Buy Rating and $28 PT on AVEO Pharmaceuticals ,2011-11-28 09:02:00-05:00,AVEO,neutral
115360.0,Biggest Gainers of the Day,2011-07-28 12:01:00-04:00,AVEO,neutral
115361.0,Jefferies Initiates Coverage of Aveo Pharmaceuticals with Buy and PT of $30,2011-07-06 07:59:00-04:00,AVEO,neutral
115362.0,"Jefferies Initiates Aveo Pharmaceuticals At Buy, $30 PT",2011-07-06 06:50:00-04:00,AVEO,neutral
115363.0,Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows,2011-06-29 04:11:00-04:00,AVEO,positive
115364.0,Stocks to Watch for 6/28/11: Fresh 52 Week Highs and Lows,2011-06-28 05:03:00-04:00,AVEO,positive
115365.0,AVEO Pharmaceuticals Announces Exercise of Over-Allotment Option for Recent Public Offering   ,2011-06-21 08:50:00-04:00,AVEO,neutral
115366.0,Top Percentage Gainers and Losers as of 2pm 06/15/11,2011-06-15 14:01:00-04:00,AVEO,negative
115367.0,Top Percentage Gainers and Losers as of 12pm 06/15/11,2011-06-15 12:04:00-04:00,AVEO,negative
115368.0,Aveo Pharmaceuticals Says 5.75M Shares Priced at $17.50 Each,2011-06-15 09:02:00-04:00,AVEO,positive
115369.0,"Upgrades Downgrades, Notable Events for June 15",2011-06-15 07:43:00-04:00,AVEO,neutral
115370.0,AVEO Pharmaceuticals Announces Proposed Public Offering of Common Stock ,2011-06-14 16:01:00-04:00,AVEO,neutral
115371.0,UPDATE: Aveo Pact Includes Filing Registration Up to $1M Shares -Bloomberg,2011-05-31 08:15:00-04:00,AVEO,positive
115372.0,"Aveo Received Cash $7.5M, Equity Investment $7.5M by J&J Unit -Bloomberg",2011-05-31 08:13:00-04:00,AVEO,neutral
115373.0,UPDATE: AVEO Pharma To Receive $15M Initial Payment; Eligible for $540M In Milestone Payments,2011-05-31 08:12:00-04:00,AVEO,neutral
115374.0,AVEO Pharmaceuticals Enters into Worldwide License Agreement with Centocor Ortho Biotech to Develop and Commercialize RON-Targeted Antibodies   ,2011-05-31 08:11:00-04:00,AVEO,positive
115375.0,J.P. Morgan Ups PT On AVEO To $25,2011-05-24 07:39:00-04:00,AVEO,neutral
115376.0,JP Morgan Raises PT On AVEO Pharmaceuticals To $25,2011-05-24 05:53:00-04:00,AVEO,positive
115377.0,Is EnCana Corporation (ECA) the Perfect Stock?,2011-05-16 09:41:00-04:00,AVEO,positive
115378.0,"Benzinga's Volume Movers (LOOP, AVEO, REDF, SFLY)",2011-04-28 10:17:00-04:00,AVEO,neutral
115379.0,AVEO Reports First Quarter 2011 Accomplishments and Financial Results   ,2011-04-28 07:06:00-04:00,AVEO,neutral
115380.0,J.P. Morgan Reports Partnership With Tivozanib A Big Win,2011-02-22 11:07:00-05:00,AVEO,positive
115381.0,Astellas and AVEO Pharmaceuticals Enter into Agreement to Develop and Commercialize Tivozanib Outside of Asia   ,2011-02-16 16:14:00-05:00,AVEO,positive
115382.0,AVEO Reports Q4 EPS of $(0.30) vs. $(0.64),2011-02-16 16:10:00-05:00,AVEO,neutral
115383.0,J.P. Morgan Healthcare Confab: Live Blog,2011-01-11 09:55:00-05:00,AVEO,neutral
